Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Hello. At this time, I would like to welcome everyone to the Exact Sciences. Third quarter, 2024 earnings conference call. (Operator Instructions) I would now like to turn the call over to Erik ...

At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 earnings conference call. [Operator ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...

We plan to accelerate growth in 2025, and our long-term outlook remains strong,” said Kevin Conroy, chairman and CEO.

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential. Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer ...

“The Exact Sciences’ team is helping eradicate cancer while strengthening our platform and growing our business efficiently,” said Kevin Conroy, CEO of Exact Sciences. “During the third quarter, we ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.